FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134525378> ?p ?o ?g. }

• W3134525378 endingPage "472.e6" @default.
• W3134525378 startingPage "472.e1" @default.
• W3134525378 abstract "Objectives Current treatments for benign vocal lesions consist mainly voice therapy and phonomicrosurgery. However, these options are not always suitable for professional voice users because of their tight performance schedule and limited time for voice rest. This study investigated vocal fold steroid injection (VFSI) as an alternative treatment. Study Design Matched case series. Methods We retrospectively enrolled 28 professional voice users (i.e., singers, actors and news anchors) who received VFSI for vocal nodules and polyps in an office setting of a tertiary teaching hospital. Outcomes were evaluated using videolaryngostroboscopy (VLS), the 10-item Voice Handicap Index (VHI-10), maximum phonation time, and acoustic and perceptual analyses before and 1 month after VFSI. Study results were compared with 56 patients of nonprofessional voice users (i.e., routine or high occupational vocal demands), matched in a 1:2 ratio by age, sex, and treatment date. Results After VFSI, VLS revealed substantial lesion resolution in 82% professional voice users. One professional voice user developed a self-limited vocal fold hematoma after VFSI. VHI-10 scores in the professional group decreased from 21 to 14 points, compared with 23 to 16 points in the non-professional group, demonstrating a significant within-group effect (P < 0.01, GEE) and a nonsignificant between-group effect (P = 0.86). Other outcomes also improved significantly after VFSI (P < 0.05), without significant differences between the two groups. Conclusion VFSI can be an effective and safe alternative treatment for professional voice users with benign vocal lesions. Current treatments for benign vocal lesions consist mainly voice therapy and phonomicrosurgery. However, these options are not always suitable for professional voice users because of their tight performance schedule and limited time for voice rest. This study investigated vocal fold steroid injection (VFSI) as an alternative treatment. Matched case series. We retrospectively enrolled 28 professional voice users (i.e., singers, actors and news anchors) who received VFSI for vocal nodules and polyps in an office setting of a tertiary teaching hospital. Outcomes were evaluated using videolaryngostroboscopy (VLS), the 10-item Voice Handicap Index (VHI-10), maximum phonation time, and acoustic and perceptual analyses before and 1 month after VFSI. Study results were compared with 56 patients of nonprofessional voice users (i.e., routine or high occupational vocal demands), matched in a 1:2 ratio by age, sex, and treatment date. After VFSI, VLS revealed substantial lesion resolution in 82% professional voice users. One professional voice user developed a self-limited vocal fold hematoma after VFSI. VHI-10 scores in the professional group decreased from 21 to 14 points, compared with 23 to 16 points in the non-professional group, demonstrating a significant within-group effect (P < 0.01, GEE) and a nonsignificant between-group effect (P = 0.86). Other outcomes also improved significantly after VFSI (P < 0.05), without significant differences between the two groups. VFSI can be an effective and safe alternative treatment for professional voice users with benign vocal lesions." @default.
• W3134525378 created "2021-03-15" @default.
• W3134525378 creator A5020653607 @default.
• W3134525378 creator A5028330227 @default.
• W3134525378 creator A5036364468 @default.
• W3134525378 creator A5080195952 @default.
• W3134525378 creator A5091839516 @default.
• W3134525378 date "2023-05-01" @default.
• W3134525378 modified "2023-10-03" @default.
• W3134525378 title "Vocal Fold Steroid Injection for Benign Vocal Lesions in Professional Voice Users" @default.
• W3134525378 cites W1640837303 @default.
• W3134525378 cites W1745418835 @default.
• W3134525378 cites W1831890917 @default.
• W3134525378 cites W1936859095 @default.
• W3134525378 cites W1980266803 @default.
• W3134525378 cites W2017055811 @default.
• W3134525378 cites W2032618634 @default.
• W3134525378 cites W2050006267 @default.
• W3134525378 cites W2059043759 @default.
• W3134525378 cites W2084816149 @default.
• W3134525378 cites W2112300834 @default.
• W3134525378 cites W2138996289 @default.
• W3134525378 cites W2141248529 @default.
• W3134525378 cites W2152489385 @default.
• W3134525378 cites W2405642103 @default.
• W3134525378 cites W2416696104 @default.
• W3134525378 cites W2522903027 @default.
• W3134525378 cites W2600610315 @default.
• W3134525378 cites W2601346077 @default.
• W3134525378 cites W2620499470 @default.
• W3134525378 cites W2623528309 @default.
• W3134525378 cites W2784123747 @default.
• W3134525378 cites W2956942412 @default.
• W3134525378 doi "https://doi.org/10.1016/j.jvoice.2021.02.002" @default.
• W3134525378 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33707029" @default.
• W3134525378 hasPublicationYear "2023" @default.
• W3134525378 type Work @default.
• W3134525378 sameAs 3134525378 @default.
• W3134525378 citedByCount "6" @default.
• W3134525378 countsByYear W31345253782021 @default.
• W3134525378 countsByYear W31345253782022 @default.
• W3134525378 countsByYear W31345253782023 @default.
• W3134525378 crossrefType "journal-article" @default.
• W3134525378 hasAuthorship W3134525378A5020653607 @default.
• W3134525378 hasAuthorship W3134525378A5028330227 @default.
• W3134525378 hasAuthorship W3134525378A5036364468 @default.
• W3134525378 hasAuthorship W3134525378A5080195952 @default.
• W3134525378 hasAuthorship W3134525378A5091839516 @default.
• W3134525378 hasConcept C141071460 @default.
• W3134525378 hasConcept C15744967 @default.
• W3134525378 hasConcept C169760540 @default.
• W3134525378 hasConcept C173988693 @default.
• W3134525378 hasConcept C26760741 @default.
• W3134525378 hasConcept C2780009028 @default.
• W3134525378 hasConcept C2780336059 @default.
• W3134525378 hasConcept C2780474809 @default.
• W3134525378 hasConcept C2909265923 @default.
• W3134525378 hasConcept C548259974 @default.
• W3134525378 hasConcept C71924100 @default.
• W3134525378 hasConceptScore W3134525378C141071460 @default.
• W3134525378 hasConceptScore W3134525378C15744967 @default.
• W3134525378 hasConceptScore W3134525378C169760540 @default.
• W3134525378 hasConceptScore W3134525378C173988693 @default.
• W3134525378 hasConceptScore W3134525378C26760741 @default.
• W3134525378 hasConceptScore W3134525378C2780009028 @default.
• W3134525378 hasConceptScore W3134525378C2780336059 @default.
• W3134525378 hasConceptScore W3134525378C2780474809 @default.
• W3134525378 hasConceptScore W3134525378C2909265923 @default.
• W3134525378 hasConceptScore W3134525378C548259974 @default.
• W3134525378 hasConceptScore W3134525378C71924100 @default.
• W3134525378 hasFunder F4320323468 @default.
• W3134525378 hasIssue "3" @default.
• W3134525378 hasLocation W31345253781 @default.
• W3134525378 hasLocation W31345253782 @default.
• W3134525378 hasOpenAccess W3134525378 @default.
• W3134525378 hasPrimaryLocation W31345253781 @default.
• W3134525378 hasRelatedWork W2038238961 @default.
• W3134525378 hasRelatedWork W2135911513 @default.
• W3134525378 hasRelatedWork W2697679210 @default.
• W3134525378 hasRelatedWork W2751620405 @default.
• W3134525378 hasRelatedWork W2988789487 @default.
• W3134525378 hasRelatedWork W3082978457 @default.
• W3134525378 hasRelatedWork W3134525378 @default.
• W3134525378 hasRelatedWork W3206121710 @default.
• W3134525378 hasRelatedWork W4311950805 @default.
• W3134525378 hasRelatedWork W4385380470 @default.
• W3134525378 hasVolume "37" @default.
• W3134525378 isParatext "false" @default.
• W3134525378 isRetracted "false" @default.
• W3134525378 magId "3134525378" @default.
• W3134525378 workType "article" @default.